Published by Josh White on 3rd February 2021
(Sharecast News) - Novel immunotherapy developer Scancell updated the market on its SCIB2 clinical development partnership with Cancer Research UK on Wednesday, reporting that due to the impact of the Covid-19 pandemic and Cancer Research UK's re-evaluation of its collaboration model, the parties had agreed to end their clinical development partnership.